[C:1]([C:5]1[O:9][C:8]([NH2:10])=[N:7][N:6]=1)([CH3:4])([CH3:3])[CH3:2].CCN(CC)CC.Cl[C:19]([O:21][CH2:22][C:23]([Cl:26])([Cl:25])[Cl:24])=[O:20]>CC#N>[Cl:24][C:23]([Cl:26])([Cl:25])[CH2:22][O:21][C:19](=[O:20])[NH:10][C:8]1[O:9][C:5]([C:1]([CH3:4])([CH3:3])[CH3:2])=[N:6][N:7]=1To a suspension of 5-tert-butyl-[1,3,4]oxadiazol-2-ylamine (Atlantic, 141 mg, 1.00 mmol) and Et3N (279 μL, 2.00 mmol) in MeCN (2 mL), 2,2,2-trichloroethyl chloroformate (207 μL, 1.50 mmol) was added in 4 portions over 1 min at RT (CARE: exotherm to −40° C.). The resulting suspension was stirred for 1 h. The suspension was filtered, washing the solid with MeCN (3 mL), and concentrated to leave a yellow-brown paste. Purification by FCC, using 0-2.5% MeOH in DCM, gave a buff foam (232 mg, 73%). 1H NMR (400 MHz, CDCl3): 1.42 (9H, s), 4.86 (2H, s).
読み込み中…
